162959-94-6

Basic information

• Product Name: 1-(thien-2-yl)cyclopropanecarboxylic acid
• Synonyms: 1-(thien-2-yl)cyclopropanecarboxylic acid;1-(Thiophen-2-yl)cyclopropanecarboxylic acid;Cyclopropanecarboxylic acid, 1-(2-thienyl)-;1-(2-Thienyl)-cyclopropanecarboxylic acid
• CAS NO: 162959-94-6
• Molecular Formula: C8H8O2S
• Molecular Weight: 168.21292
• Mol File: 162959-94-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(thien-2-yl)cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(thien-2-yl)cyclopropanecarboxylic acid(162959-94-6)
• EPA Substance Registry System: 1-(thien-2-yl)cyclopropanecarboxylic acid(162959-94-6)

Safety Data

• Hazardous Substances Data: 162959-94-6(Hazardous Substances Data)

Usage

Uses

1-(Thiophen-2-yl)cyclopropanecarboxylic acid is a useful chemical for research as it has been used to study halogen bonding in protein-ligand interactions.

Upstream product

• 20893-30-5 2-cyanomethylthiophene 
• 57382-97-5 ethyl thiophen-2-ylacetate 
• 950604-72-5 C₁₀H₁₂O₂S 
• 162959-93-5 1-(thiophen-2-yl)cyclopropanecarbonitrile 

Relevant articles and documents

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] There is provided a compound which can be used for therapy of diseases in which 11 β-hydroxysteroid dehydrogenase type 1(11β-HSD1) participates, in particular diabetes, insulin resistance. [Means for Solution] It has been found that a triazole derivative wherein the triazole ring is substituted with a trisubstituted methyl group in the 2-position or a pharmaceutically acceptable salt thereof has a strong 11β-HSD1 inhibitory activity. Moreover, the triazole derivative of the invention exhibits an excellent blood-glucose level-lowering action and hence can be used for therapy of diabetes, insulin resistance.